AI Insight
Researchers at Brunel University of London have found that a protein commonly used as a clinical biomarker for tumor proliferation may also play a role in maintaining chromosomal stability. The study suggests this protein could help prevent chromosome segregation errors, which are a known driver of cancer development and progression. This dual function positions the protein as a potential therapeutic target beyond its current diagnostic use.
Why it matters
If confirmed through further research, this finding could open new avenues for cancer treatment by targeting a protein already well-characterized in clinical settings. Repurposing knowledge of an existing biomarker for therapeutic development could accelerate the path toward new interventions.
A protein doctors routinely use to measure how aggressively tumors are growing may also help prevent the chromosome errors that drive cancer, new research by academics at Brunel University of London suggests.
Source: Common cancer protein may be therapeutic target, study finds